Gilead Sciences Inc (NAS:GILD)
$ 67.26 -0.6 (-0.88%) Market Cap: 83.80 Bil Enterprise Value: 105.02 Bil PE Ratio: 186.83 PB Ratio: 4.78 GF Score: 77/100

Gilead Sciences Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 13, 2021 / 06:00PM GMT
Release Date Price: $68.91 (+2.16%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Okay. Good afternoon. And welcome to the final day of the BofA Healthcare Conference, Virtual Vegas, as it were. My name is Geoff Meacham. I'm a senior biopharma analyst here at BofA. And I have Jason Zemansky from my team with me as well. And we're thrilled to have CFO, Andy Dickinson from Gilead. Andy, welcome.

Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO

Thank you. Thanks for having me. Appreciate it once again.

Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Yes. So what we'll do is, we'll do some questions here with Andy. We won't get into anything post the quarter. Obviously, we've talked about that a week or so ago. But let's get right into it, Andy.

Questions & Answers

Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

When you think about the HIV business. It's a flagship

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot